Lexeo Therapeutics, Inc. (LXEO)

Over the past six months, Lexeo Therapeutics completed a public offering and private placement, raising approximately $153.8 million. The company announced progress in FDA discussions and positive interim clinical data for LX2006. Lexeo hosted a virtual KOL event at the 22nd Global Cardiovascular Clinical Trialists Forum and presented at the 44th Annual J.P. Morgan Healthcare Conference. Lexeo Therapeutics announced a research collaboration to explore targeted cardiac delivery of AAV gene therapy. Preliminary data from the HEROIC-PKP2 Phase I/II clinical trial of LX2020 was released, and the stock fell significantly. Analysts have issued multiple "Buy" or "Outperform" ratings for LXEO, with price targets ranging from $10.00 to $30.00.

Lexeo Therapeutics' products and services do not exhibit typical demand seasonality. The demand for its pipeline candidates is driven by the progression of clinical trials, regulatory approvals, and the prevalence of the diseases they aim to treat, rather than seasonal fluctuations.

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company based in New York City, focused on transforming healthcare by applying pioneering science to treat cardiovascular diseases. The company operates within the biotechnology sector and the gene therapy industry, focusing on genetically defined cardiovascular diseases and a subgroup of Alzheimer's disease. Lexeo's pipeline includes LX2006 for Friedreich's ataxia cardiomyopathy, LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, LX2021 for inherited cardiac muscle disorders, and LX1001 for APOE4-associated Alzheimer's disease.

Lexeo Therapeutics, Inc. is headquartered in New York, New York, United States. The company's foundational science stems from partnerships and exclusive licenses with academic laboratories at Weill Cornell Medicine and the University of California San Diego.

Lexeo Therapeutics generally holds a positive brand reputation among analysts, with a consensus rating of "Moderate Buy". The company has received 1 strong buy rating, 8 buy ratings, and 1 sell rating from analysts. Positive interim data for LX2006 and LX2020 have generally contributed positively to its reputation, and the FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia further enhances its standing. The significant drop in stock price following the interim LX2020 data release indicates that market expectations were not fully met, potentially impacting short-term investor sentiment. LXEO insiders have sold stock on the open market 20 times, with no purchases, which could be perceived negatively by some investors.

Lexeo Therapeutics, Inc. has a significant institutional ownership, with 67.63% of its stock held by institutional shareholders, insiders own 9.87%, and retail investors hold 22.50%. As of January 9, 2026, there are 197 institutional owners and shareholders holding a total of 51,402,105 shares. Major institutional owners include Janus Henderson Group Plc, Frazier Life Sciences Management, L.P., and Balyasny Asset Management L.P. Longitude Capital Partners IV LLC is noted as the largest individual shareholder, owning 2.57 million shares, representing 3.52% of the company.